Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:54:04 EDT Tue 30 Apr 2024
Enter Symbol
or Name
USA
CA



Q:RGLS - REGULUS THERAPEUTICS INC - http://www.regulusrx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RGLS - Q0.12.40·4.802.32.52+0.104.1214.24691,1642.44  2.60  2.413.79  1.08Apr 29Mar 2115 min RT 2¢

Recent Trades - Last 10 of 1164
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-21 16:05U:RGLSNews ReleaseRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
2024-03-12 06:32U:RGLSNews ReleaseRegulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
2024-03-12 06:30U:RGLSNews ReleaseRegulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2024-01-02 16:05U:RGLSNews ReleaseRegulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-11-22 08:00U:RGLSNews ReleaseRegulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-09 16:05U:RGLSNews ReleaseRegulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
2023-11-02 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-10-19 08:00U:RGLSNews ReleaseRegulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-09-20 07:00U:RGLSNews ReleaseRegulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-09-13 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-09-05 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
2023-08-23 08:00U:RGLSNews ReleaseRegulus Therapeutics to Host Virtual Investor Event on September 6, 2023
2023-08-08 16:05U:RGLSNews ReleaseRegulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
2023-08-02 08:00U:RGLSNews ReleaseRegulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-07-18 08:00U:RGLSNews ReleaseRegulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
2023-06-27 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2023-06-23 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
2023-06-20 08:00U:RGLSNews ReleaseRegulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
2023-06-12 08:00U:RGLSNews ReleaseRegulus Therapeutics Strengthens Research & Development Leadership
2023-05-16 08:00U:RGLSNews ReleaseRegulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)